Compare iShares MSCI Indonesia ETF (EIDO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Stryker Corporation — how do they compare? iShares MSCI Indonesia ETF trades at $12.18, while Stryker Corporation trades at $318 (market cap $121.31B). The key difference: Stryker Corporation pays a 1.11% dividend while iShares MSCI Indonesia ETF pays none, and Stryker Corporation is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | SYK | |
|---|---|---|
52-Week High | $19.22 | $403.53 |
52-Week Low | $10.80 | $282.58 |
Market Cap | — | $121.31B |
Sector | — | Technology |
Enterprise Value | — | $133.07B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
Stryker (SYK) trades at $329.38, up 5.84% in the last session, yet technical indicators signal a bearish trend. The company reported a Q1 2026 earnings miss due to a temporary cyber disruption but maintained full-year guidance, with strong profitability margins and robust cash flow. Recent news highlights expansion of its Mako robotics platform, reinforcing its innovation-led growth strategy in the medical technology sector.
The investment outlook is positive based on strong fundamentals and analyst consensus, but near-term risks include competitive pressures and execution challenges. With a consensus price target of $388.44 representing ~18% upside, the stock offers value for long-term investors, though volatility may persist until Q2 earnings clarify the post-disruption recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
